The association of anxiety and depression with perioperative and oncologic outcomes among patients with clear cell renal cell carcinoma undergoing nephrectomy.

Anxiety and depression have been associated with inferior overall survival for several malignancies, including metastatic renal cell carcinoma (RCC). However, there is minimal data evaluating this association for localized RCC. We evaluated the association of anxiety or depression with survival in patients with surgically treated localized clear cell RCC (ccRCC).

We reviewed our institutional nephrectomy registry of 1,990 adults who underwent radical or partial nephrectomy for unilateral, sporadic, nonmetastatic ccRCC between 1995 and 2011. Baseline anxiety and depression were identified using ICD-9 codes. Associations of anxiety or depression with 30-day complications and oncologic outcomes were evaluated using Cox proportional hazards models as well as adjustment for propensity score (PS) quintile and re-weighting by stabilized inverse probability weights.

A total of 197 (10%) patients were identified with a diagnosis of anxiety or depression. Median follow-up among survivors was 10.0 (IQR 7.3-13.6) years, during which time 864 patients died, including 363 from RCC. After PS adjustment, clinical and pathologic features were well balanced between groups. Patients with anxiety or depression had increased overall 30-day complications compared to those without (17% vs. 11%, P = 0.011). No significant differences were noted in time to local ipsilateral recurrence (P = 0.54), distant metastases (P = 0.96), or death from RCC (P = 0.42) between patients with vs. without anxiety or depression, while patients with anxiety or depression trended toward worse overall survival (hazard ratio 1.29, 95%CI 0.98-1.69, P = 0.065).

Neither anxiety nor depression were significantly associated with oncologic outcomes among patients who underwent surgery for localized ccRCC. The trend toward worse overall survival among patients with anxiety or depression warrants further investigation.

Urologic oncology. 2019 Nov 21 [Epub ahead of print]

Vignesh T Packiam, Mark D Tyson Ii, Matvey Tsivian, Christine M Lohse, Stephen A Boorjian, John C Cheville, Brian A Costello, Bradley C Leibovich, R Houston Thompson

Mayo Clinic, Department of Urology, Rochester, MN., Mayo Clinic, Department of Urology, Scottsdale, AZ., Mayo Clinic, Department of Health Sciences Research, Rochester, MN., Mayo Clinic, Department of Laboratory Medicine and Pathology, Rochester, MN., Mayo Clinic, Department of Oncology, Rochester, MN., Mayo Clinic, Department of Urology, Rochester, MN. Electronic address: .